PTIX Protagenic Therapeutics Profit After Tax

Corporate emblem and logo of Protagenic Therapeutics (PTIX)

An innovative approach to neuron regulation provides Protagenic Therapeutics (PTIX) with a competitive edge in treating mental disorders, which supports the company's annual net profit dynamics. Currently, -0.01 represents the latest metric reading. The business foundation relies on the expansion of PT00114 synthetic peptides; however, the lack of revenue and dependence on investment create significant existential risks for the project.

PTIX (protagenic.com) Company Net Income history from 07/04/2022 to 01/10/2026

Financial and market metric breakdowns for protagenic.com (PTIX)

- stock value and consensus price forecast:
Market Price Protagenic Therapeutics, Inc.|PTIX - Price Target Chart
- market capitalization data:
Market Valuation Protagenic Therapeutics, Inc.|PTIX - Total Company Value
- issuer book value statistics:
Accounting Value of a Share Protagenic Therapeutics|PTIX - Company Book Value|Market-to-Book Ratio protagenic.com|PTIX - Cumulative Company Assets
- debt and liquidity details:
Aggregate Debt to Capital Protagenic Therapeutics|PTIX - Long-Term Debt to Capital|Short-Term Debt to Capital Protagenic Therapeutics, Inc.|PTIX - Company Aggregate Debts|Debt to Net Assets Protagenic Therapeutics, Inc.|PTIX - Company Long-Term Debts|Short-Term Debt Protagenic Therapeutics|Immediate Liquidity Ratio protagenic.com
- net income and valuation multiples indicators:
PTIX - Net Profit
Fundamental valuation:PTIX (Protagenic)
Flagship merchandise of protagenic.com

To select high-quality assets, an investor must confirm capital stability through an objective assessment of the daily share of net profit. This indicator measures daily business efficiency, which for Protagenic Therapeutics (PTIX), a company investing in neurobiological research for hormone therapy, allows for the tracking of partnership monetization and the mitigation of accounts receivable risks by analyzing the company's net profit dynamics.

Direct competitors

Company Net Income Biogen Idec (BIIB)|Company Net Income Neurocrine Biosciences|regencellbioscience.com - Profit After Tax|Company Net Income Axsome Therapeutics, Inc. (AXSM)|ACAD (ACADIA Pharma) - Final Profit|Company Net Income Xenon Pharmaceuticals Inc XENE|Viking Therapeutics Corp (VKTX) - Company Net Income|SUPN: Net Income|catalystpharma.com - Profit After Payment of Taxes|DNLI: Net Profit|Harmony Biosciences Inc (HRMY) - Net Profit|BHVN (Biohaven Pharmaceutical) - Net Profit|AMLX - Annual Net Income|Net Profit TRVI|PRAX - Company Net Income|Company Net Income Anavex Life Sciences Corp. AVXL|CBLL: Company Profit|Prothena Biosciences - Net Profit|Net Financial Result Alector, Inc. ALEC|ANNX: Net Profit|Net Income Omeros|Net Income NGNE|ACIU: Final Profit|Net Income VYGR (Voyager Pharma)|Profit After Payment of Taxes NMRA|Net Profit SCLX (Scilex Holding Company)|Final Profit TVGN|Alpha Cognition Corp - Net Profit|Company Net Income cogrx.com|Inhibikase (IKT) - Company Net Income|Cassava Pharma - Final Profit|ASRT (Assertio Holdings) - Net Profit|Net Profit Coya|Company Net Income Vistagen Therapeutics (VTGN)|OVID: Profit After Tax|Net Profit ABOS (Acumen Pharma)|CervoMed Corporation (CRVO) - Company Net Income|ATHE: Net Income|CLNN - Net Profit|PEPG (pepgen.com) - Net Income|JUNS: Profit After Payment of Taxes|RLMD (Relmada) - Net Profit|Annovis Bio Corporation (ANVS) - Net Financial Result|Net Profit GRCE|Net Income fireflyneuro.com AIFF|Company Net Income Klotho Neurosciences KLTO|Net Financial Result NeuroSense Therapeutics Ltd (NRSN)|RVPH - Company Net Income|Profit After Tax MTVA|NRXS (NeurAxis, Inc.) - Net Income|HSDT: Profit After Payment of Taxes|PASG (Passage Bio Inc.) - Net Profit|Neuphoria (NEUP) - Net Financial Result|Net Income NERV (Minerva Neurosciences Corp)|Athira Pharma Corp - Company Profit|Company Net Income Addex Therapeutics ADXN|ALZN: Company Profit|Cyclerion - Net Profit|Company Net Income Pasithea Therapeutics|CRGT (cortigent.com) - Net Income|Avenue Therapeutics Inc (ATXI) - Net Profit|Company Net Income Brainstorm Cell|CARA: Final Profit|Company Net Income Chromocell Therapeutics Corp. (CHRO)|ELYM - Company Net Income|Company Net Income Intra-Cellular Therapies, Inc. ITCI|LBPH (Longboard) - Profit After Tax|MRNS - Company Net Income|Final Profit NKGN (nkgenbiotech.com)|NeuroBo Pharmaceuticals, Inc. (NRBO) - Company Net Income|Company Net Income Sage Therapeutics Inc. (SAGE)|Net Income SNPX|TRVN (Trevena Inc) - Profit After Payment of Taxes|Net Profit VIGL|Net Profit Anew Medical Inc. (WENA)|Net Profit CERE (Cerevel Therapeutics, Inc.)